Should I buy Visteon (VC) stock or is it too late?
⭐ The most reliable of them, either direction: RBC Capital — 57% of its targets hit on this sector (176 calls tested). It aims for $129 (+28 %), call made on July 25, 2026, maturing on July 25, 2027 (34 d ago).
Firm-by-firm track record on Visteon
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Deutsche Bank | 71 % | +39.8 % | 7 | $132 +31% |
| UBS | 75 % | +21.1 % | 12 | $130 +29% |
| Barclays | 81 % | +17.9 % | 16 | $145 +44% |
| Wells Fargo | 69 % | +6.5 % | 26 | $134 +33% |
| RBC Capital | 62 % | +4.5 % | 13 | $129 +28% |
| JP Morgan | 56 % | +4.1 % | 9 | $170 +68% |
| Goldman Sachs | 50 % | -15.8 % | 8 | $118 +17% |
| Baird | 25 % | -15.9 % | 8 | $121 +20% |
✅ Reasons to believe
- 73% of analysts rate it a buy (Buy consensus, 11 ratings) — a sign of market conviction.
- Median price target $131, i.e. +30% from the current price ($101).
- The most reliable firm on VC, Barclays (81% hit rate, 16 scored calls), targets $145 (call made on June 22, 2026, maturing on June 22, 2027) (+44%) in its most recent call, and $135 (call made on October 10, 2025, maturing on October 10, 2026) (+34%) in the one coming due soonest.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 11 ratings, 3 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- Volatile stock: sharp swings — including steep drops — are part of its profile.
The analyst consensus on VC
Median target $131 (+30%) · 11 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Visteon now?
We won't decide for you. The facts: 73% of analysts rate it a buy, median target $131 (+30%), and Barclays (most reliable on VC, 81%) targets $145. Weigh that against valuation and volatility. This is not personalized advice.
Is it too late to invest in Visteon?
Not according to analysts: the median target ($131) is still +30% above the current price ($101) (most reliable on VC: Barclays, 81%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Visteon still worth investing in?
It depends on the gap between the price ($101) and its estimated value: analysts target $131 on median (+30%), with 73% buys (most reliable on VC: Barclays, 81%). Cross-check with their real reliability on VC and the cautions above. Information, not advice.
What's the main risk in buying VC?
The consensus is not unanimous: of 11 ratings, 3 are neutral.
→ Go deeper: the full Visteon profile (consensus, analyst reliability, price target, performance).